Key result
High-dose doxorubicin linked to early cardiotoxicity in ~44% of young sarcoma patients at 1 year.
Why the study?
Adolescents and young adults with sarcomas often receive high-dose doxorubicin, but data on early cardiotoxicity in this population are limited.
Cohort (n=56)
Single-blind
No
Over one-third of adolescent and young adult sarcoma patients receiving high-dose doxorubicin experience early subclinical echocardiographic declines within one year, underscoring the clinical utility of monitoring left ventricular strain and wall thickness before overt LVEF drop occurs.
Early subclinical LV changes support serial strain monitoring in doxorubicin-treated AYA sarcoma patients; leaves open optimal cardioprotection strategies pending randomized trials.
Background Adolescents and young adults (AYAs) with sarcomas often receive high-dose doxorubicin (Dox), but data on early cardiotoxicity in this population are limited. Objectives To prospectively evaluate early echocardiographic changes in AYAs with sarcoma treated with high-dose Dox. Methods AYAs (15–39 years) with sarcoma treated at a tertiary cancer centre (2018–22) were prospectively enroled. Echocardiograms were performed at baseline, 1 and 2 years after cancer therapy initiation and interpreted by a single cardiologist. The primary endpoint was a >10% absolute reduction in left ventricular ejection fraction (LVEF), an absolute LVEF <50%, or >10% decrease in LV wall thickness/dimension (LVWT/D) ratio from baseline. Secondary endpoints included longitudinal changes in cardiac structure, chamber volumes, systolic and diastolic function, and strain. Results Of 70 patients, 56 completed at least two of three study echocardiograms (median age 22.6 [IQR, 17.6–30.5] years; 41% female, 84% white). Median cumulative Dox dose was 450 (IQR, 370–450) mg/m2; 75% received dexrazoxane. The primary endpoint was met by 44.4% at 1 year and 27.5% at 2 years, driven primarily by LVWT/D ratio decline (37% at 1 year, 25% at 2 years), while significant LVEF decline was observed in 11.1% and 2.5%, respectively. Significant absolute changes at 1 year included LVEF (−2.73 ± 4.3%, P < .001), global longitudinal strain magnitude (−1.37 ± 2.56%, P = .002), septal e′ (−1.75 ± 2.48 cm/s, P < .001), and lateral e′ (−2.78 ± 3.44 cm/s, P < .001), persisting at 2 years. One patient (1.8%) developed ventricular fibrillation and heart failure with reduced ejection fraction, with LVEF recovery within 1 year. Conclusions Over one-third of AYAs with sarcoma met the primary endpoint at 1 year, with half of these abnormalities persisting at 2 years, primarily driven by LVWT/D ratio reductions. Subclinical changes in strain and diastolic function were observed, reflecting the broad cardiac impact of high-dose Dox in this population.
No takes yet. Share an insight, caveat, or question.
Koutroumpakis et al. (2026) conducted a cohort in Sarcoma (n=56). High-dose doxorubicin was evaluated on Composite of >10% absolute reduction in LVEF, absolute LVEF <50%, or >10% decrease in LVWT/D ratio from baseline. High-dose doxorubicin exposure led to early echocardiographic signs of cardiotoxicity in 44.4% of adolescent and young adult sarcoma patients at 1 year, primarily driven by left ventricular wall thickness-to-dimension ratio declines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: